Sagimet Biosciences Inc (SGMT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$10.94+0.18%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SGMT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SGMT — officer change
Dated 2026-06-12
Director — Tim Walbert: Mr. Walbert resigned due to other commitments.
Why it matters: Starting this trial is key for Sagimet's future. It shows progress in drug development.
Supportive ifA press release confirming the start of the Phase 3 trial for denifanstat.
Worry ifNo announcement or delay in starting the Phase 3 trial for denifanstat.
Why it matters: Starting this trial is key for Sagimet's focus on dermatology. It could lead to a new treatment option for acne.
Supportive ifThe Phase 3 trial for denifanstat in moderate to severe acne begins as planned in the second half of 2026.
Worry ifThe trial does not start as planned due to regulatory delays or other issues.
Why it matters: A strong cash position is crucial for funding ongoing trials and operations. It shows financial health.
Supportive ifCash, cash equivalents, and marketable securities are over $250 million. This means funding is secure through 2028.
Worry ifCash reserves fell below $200 million. This raises worries about funding for ongoing projects.
Why it matters: Results will show if this new treatment can effectively target acne. Positive results could support further development.
Watch forPositive results from the Phase 1 trial of TVB-3567 are announced, indicating potential for a Phase 2 trial.
Also watch forThe Phase 1 trial of TVB-3567 had bad results. This makes its development uncertain.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$188 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $722 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,022 loss on $10,000 · 50.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.